| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
1 Division of Nephrology and Hypertension, and 2 Departments of Medicine, Physiology and Biophysics, University of California, Irvine, California 92697
Chronic renal failure (CRF) is associated with profound abnormalities of lipid metabolism and accelerated arteriosclerotic cardiovascular disease. In a recent study, we found marked downregulation of hepatic lecithin-cholesterol acyltransferase, or LCAT, expression, which can account for impaired HDL maturation and depressed HDL cholesterol concentration in CRF. Here, we report on the effect of CRF on acyl-CoA:cholesterol acyltransferase (ACAT) expression. ACAT is an intracellular enzyme that catalyzes esterification of free cholesterol to cholesterol ester for storage or secretion. ACAT plays a major role in hepatic production and release of VLDL, intestinal absorption of cholesterol, foam cell formation, and atherogenesis. We examined hepatic expression of ACAT-1 and ACAT-2 mRNA (Northern blot) and protein (Western blot) abundance and total ACAT activity in male CRF rats (6 wk after 5/6 nephrectomy) and sham-operated controls. The CRF animals showed a significant reduction in creatinine clearance, marked hypertriglyceridemia, modest hypercholesterolemia, and significant upregulation of hepatic tissue ACAT-2 protein and mRNA abundance. In contrast, hepatic ACAT-1 mRNA and protein abundance were unaffected by CRF. Upregulation of ACAT-2 expression was accompanied by a significant increase in hepatic ACAT activity and a significant decrease in hepatic microsomal and whole liver free cholesterol concentration. Thus CRF results in significant upregulation of hepatic ACAT-2 (but not ACAT-1) expression and ACAT activity, which may, in part, contribute to the associated lipid disorders.
uremia; renal insufficiency; hyperlipidemia; cholesterol; atherosclerosis; cardiovascular disease
This article has been cited by other articles:
|
|
 |
|
  H. Lu and C. Klaassen Gender Differences in mRNA Expression of ATP-Binding Cassette Efflux and Bile Acid Transporters in Kidney, Liver, and Intestine of 5/6 Nephrectomized Rats Drug Metab. Dispos., January 1, 2008; 36(1): 16 - 23. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. D. Vaziri Dyslipidemia of chronic renal failure: the nature, mechanisms, and potential consequences Am J Physiol Renal Physiol, February 1, 2006; 290(2): F262 - F272. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Liang, C. H. Kim, and N. D. Vaziri HMG-CoA reductase inhibition reverses LCAT and LDL receptor deficiencies and improves HDL in rats with chronic renal failure Am J Physiol Renal Physiol, March 1, 2005; 288(3): F539 - F544. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. D. Vaziri and K. Liang ACAT inhibition reverses LCAT deficiency and improves plasma HDL in chronic renal failure Am J Physiol Renal Physiol, November 1, 2004; 287(5): F1038 - F1043. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. D. Vaziri, C. H. Kim, B. Dang, C.-D. Zhan, and K. Liang Downregulation of hepatic acyl-CoA:diglycerol acyltransferase in chronic renal failure Am J Physiol Renal Physiol, July 1, 2004; 287(1): F90 - F94. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Jolma, P. Koobi, J. Kalliovalkama, M. Kahonen, M. Fan, H. Saha, H. Helin, T. Lehtimaki, and I. Porsti Increased calcium intake reduces plasma cholesterol and improves vasorelaxation in experimental renal failure Am J Physiol Heart Circ Physiol, November 1, 2003; 285(5): H1882 - H1889. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Visit Other APS Journals Online |
